I can't figure out what the issue is here other than maybe a plasma shortage could be negative for the stock.
I noticed GRFS was trending down at same time as KRMD but has had a nice little bounce recently - I thought their decline could have been plasma shortage related.
KRMD stock had a meteoric rise and was probably due for a breather. A 50% or so drop from the highs can be hard to take but the stock ran from < 1.50.
I see the market cap is about 6x their estimated 2022 revenues. Maybe the market perceives this as appropriate at this time.
One of the reasons I owned this was I thought their path to the 50 million in revs was more or less easily achievable. I also thought that they had, and do have, many hands in the fire with large pharma trials and the market was not pricing any of that in. I do think it only a matter of time before they have a positive "surprise" in that a new drug approval, or expanded indication for an existing drug will benefit them greatly.
No position at this time. I think the stock should have significant support in this $6-$7 range. All cash tied up (ATGN, VNTR, IPATF, CLPT). Still watching.
Market Data 
Markets 
AI
